- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07469020
CLE-PAD: Prevalencia de la EAP en Pacientes con Estenosis Espinal Lumbar Quirúrgica (CLE-PAD)
CLE-PAD : Prevalencia de la Enfermedad Arterial Periférica de las Extremidades Inferiores en Pacientes con Estenosis Espinal Lumbar Quirúrgica
The goal of this interventional study is to evaluate the rate of existing lower limb peripheral artery disease (PAD) in patients with surgically lumbar spinal stenosis (LSS). PAD and LSS can present similar symptoms and it can be difficult to diagnose PAD using conventional methods, depending on the location of the arterial disease. The main questions it aims to answer are :
- What's the prevalence of PAD in LSS patients?
- Which exam among routine tools is the most accurate to diagnose PAD in this population? Around their surgery for LSS (a few weeks before or after), participants will be included in a vascular medicine service. After checking of eligibility criteria, they will undergo a contrast-enhanced CT scan for the diagnosis of PAD and various routine diagnostic tests: Doppler ultrasound, treadmill tests, pressure index, pulse palpation.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Lumbar spinal stenosis (LSS) is a debilitating degenerative condition in older people associated with lower back pain, pain in the lower limbs and a reduced quality of life. LSS can be treated surgically, but the results are mixed: 35% of patients report low satisfaction one year after surgery. The symptoms of LSC in the lower limbs can mimic those associated with peripheral arterial disease (PAD). The prevalence of PAD in the LSC population varies between 4.1% and 67.8% depending on the diagnostic tests used and the populations studied. Thus, the precise analysis of the prevalence of PAD and the sensitivity and specificity of PAD diagnostic tests in this population remain to be determined. These analyses would help to optimise PAD diagnostic tools, while possibly providing an explanation for the post-operative persistence of functional discomfort in CLE patients. Furthermore, a better understanding of the vascular system in the CLE population offers hope for optimising patient care, both from a medical and a medico-economic point of view.
The experimental visit takes place as soon as possible after receipt of the biological assessment and within a maximum period of 3 months. During this visit, specific research examinations will be performed, including stress tests (stress TcPO2 according to the modified Strandness protocol and stress TcPO2 according to the Gardner-Skinner increasing load protocol), as well as an injected scan of the aorta of the lower limbs. The pseudonymised CT scan will be sent to the sponsor for blind review. A follow-up telephone call will be made between 7 and 10 days after the CT scan to detect the occurrence of any adverse events. The study will then be completed for the participant.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Marie-Laure Gervais
- Número de teléfono: +33299284321
- Correo electrónico: marie-laure.gervais@chu-rennes.fr
Ubicaciones de estudio
-
-
-
Lille, Francia
- Aún no reclutando
- Groupement des Hôpitaux de l'Institut Catholique de Lille
-
Contacto:
- Marjolaine Talbot
- Número de teléfono: +33320225000
- Correo electrónico: talbot.marjolaine@ghicl.net
-
Investigador principal:
- Marjolaine Talbot
-
Paris, Francia
- Reclutamiento
- Groupe hospitalier Paris Saint Joseph
-
Contacto:
- Ewa Tuleja
- Número de teléfono: +33144127137
- Correo electrónico: etuleja@ghpsj.fr
-
Investigador principal:
- Ewa Tuleja
-
Rennes, Francia
- Reclutamiento
- CHU Rennes
-
Contacto:
- Marie Charasson
- Número de teléfono: +33299284321
- Correo electrónico: marie.charasson@chu-rennes.fr
-
Investigador principal:
- Marie Charasson
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Presenting with a lumbar spinal stenosis with surgical indication, either unoperated or operated on less than 3 months ago
- Affiliated with a social security scheme
- Having received oral and written information about the protocol and having signed a written consent form to participate in this research.
Exclusion Criteria:
-
emergency surgical care
-
Contraindication to contrast enhanced CT scan
- Stroke or myocardial infarction (MI) within the last 3 months
- Known severe or poorly tolerated arrhythmia
- Known severe or symptomatic left ventricular outflow obstruction
- Decompensated heart failure
- History within the last 3 months of venous thromboembolic disease, myopericarditis, endocarditis, aortic dissection or intracardiac thrombus
- Severe uncontrolled hypertension (BP > 200/110 mmHg)
- Inability to walk on the treadmill
- Major lower limb amputation
- Adult subject to legal protection
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Participantes
|
contrast-enhanced CT scan |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of patients with PAD identified during the contrast enhanced CT scan
Periodo de tiempo: 3 months
|
Number of patients with PAD identified during the contrast enhanced CT scan. PAD will be defined by the presence of at least one arterial stenosis ≥ 50% on the arterial axes located from the abdominal aorta to the origin of the tibiofibular arterial trunk, as determined by CT scan of the aorta and lower limbs in accordance with the recommendations. |
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Efficiency of diagnosis test "pulse"
Periodo de tiempo: 3 months
|
determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "pulse" : the absence of distal pulses will be considered pathological |
3 months
|
|
Efficiency of diagnosis test "systolic pressure index"
Periodo de tiempo: 3 months
|
determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "systolic pressure index" : A resting systolic pressure index ≤ 0.90 will be considered pathological in accordance with the recommendations. |
3 months
|
|
Efficiency of diagnosis test "toe systolic pressure index"
Periodo de tiempo: 3 months
|
determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "toe systolic pressure index" : A resting toe systolic pressure index ≤ 0.70 will be considered pathological in accordance with the recommendations. |
3 months
|
|
Efficiency of diagnosis test "Aorto-iliac and lower limb Doppler ultrasound"
Periodo de tiempo: 3 months
|
determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "Aorto-iliac and lower limb Doppler ultrasound " : velocimetric criteria for stenosis and Saint-Bonnet B and CD, E and 0 Doppler curves considered pathological (i.e. AOMI) in accordance with recommendations . |
3 months
|
|
Efficiency of diagnosis test "exercise oxymetry"
Periodo de tiempo: 3 months
|
determination of the sensitivity and specificity, positive predictive value and negative predictive value of the diagnostic test "exercise oxymetry " : Delta from rest oxygen pressure (DROP) ≤ -15 mmHg will be considered pathological (i.e. AOMI) in accordance with the recommendations. . |
3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Marjolaine Talbot, Groupement des Hôpitaux de l'Institut Catholique de Lille
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 35R24_8825_04_CLE-PAD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .